Pharmacy Board Recalls Medfil Mebendazole 100mg
By Ndeamoh Mansaray & Tamba Tengbeh
Sierra Eye Salone on Monday 28th November ,2022 posted on ,” Pharmacy Board recalls Medfill (MEBENDAZOLE 100mg) from the Sierra Leone Market due to alleged bleeding and death. They are currently supervising the quarantine of the said product so that no patient will have access to it pending the conclusion of the ongoing investigation.”
Responding to the story, the Outreach Coordinator of the Sierra Leone Pharmacy Board, Mambu Ibrahim Kamara confirmed that the Recall of MedFil (MEBENDAZOLE 100mg) from the Sierra Leone Market due to alleged Bleeding and Death story was “true”
He noted that the Pharmacy Board received a Suspected Adverse Drug Reaction report of bleeding and death allegedly linked to Mebfil (Mebendazole 100mg) last week.
“The reason board has started an investigation and requested the Marketing Authorization Holder (MAH) to recall all Mebfil products from the Sierra Leone market, including all distribution points such as hospitals, wholesalers, pharmacies, drug stores, and patent medicine shops,” Kamara averred.
The Board currently supervising the quarantine of the said product so that no patient or consumer will have access to it pending the conclusion of the ongoing investigation according to the Outreach Coordinator.
Kamara added that in the press release on 28th November 2022, the board has called on all healthcare professionals not prescribe Mebfil to patients and the general public to dispense and not to take Mebfil until the investigation is completed and a formal communication is released by the Pharmacy Board of Sierra Leone, Ministry of Health and Sanitation.
Pharmacy Board of Sierra Leone (PBSL) is mandated to ensure that manufacturer’ representatives or marketing authorization holders (MAH) have a functional pharmacovigilance system in place so that they can assume responsibility and liability for their products on the market and to ensure that appropriate actions are taken when necessary. The manufacturer representative or MAH should ensure that all information that is important to the benefit-risk ratio of a product is reported promptly to PBSL in accordance with PBSL’s PV regulatory obligations.